Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Schiffer

Medical Oncology Detroit, MI Medical Doctor

NPI 1417994112 CMS profile 64910

4100 John R St, Detroit, MI 48201

Open in the dashboard

General payments

$164,656

112 records reported · program years 2019–2025

Research payments

$3,800

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$451,959 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Charles Schiffer of Detroit, MI is reported in the CMS Open Payments database as having received $164,656 across 112 general payments and $3,800 in research payments paid to them. Separately, studies naming them as principal investigator received $451,959 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,546 11
2024 General $27,082 29
2023 General $6,508 1
2022 General $13,096 6
2022 Research $3,800 1
2021 General $34,611 15
2020 General $27,484 13
2019 General $39,330 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Schiffer
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Charles Schiffer were reported at $16,546. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Charles Schiffer Medical Oncology median Middle half National median
2019 $39,330 $968 $140–$6,658 $163
2020 $27,484 $747 $102–$5,891 $114
2021 $34,611 $430 $50–$4,098 $132
2022 $13,096 $812 $127–$4,907 $149
2023 $6,508 $957 $144–$5,248 $160
2024 $27,082 $1,042 $149–$5,650 $164
2025 $16,546 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $27,773 18 payments
  2. Celgene Corporation $22,716 13 payments
  3. E.R. Squibb & Sons, L.L.C. $18,969 18 payments
  4. Urogen Pharma, Inc. $14,579 8 payments
  5. AstraZeneca Pharmaceuticals LP $13,605 4 payments
  6. Astellas Pharma Global Development $12,687 7 payments
  7. AbbVie, Inc. $7,868 12 payments
  8. Novartis Pharmaceuticals Corporation $7,284 5 payments
  9. Dova Pharmaceuticals $7,248 6 payments
  10. Agios Pharmaceuticals, Inc. $5,657 8 payments
  11. Other $26,271 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $146,654 55 payments
  2. Travel and Lodging $13,640 31 payments
  3. Honoraria $2,400 1 payment
  4. Food and Beverage $1,962 25 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $24,398 16 payments
  2. XOSPATA $16,478 9 payments
  3. Doptelet $7,248 6 payments
  4. LYNPARZA $6,508 1 payment
  5. ONUREG $6,116 3 payments
  6. JCAR017 $6,000 3 payments
  7. TIBSOVO $5,657 8 payments
  8. Venclexta $5,505 11 payments
  9. ABL002 $5,502 2 payments
  10. OPDIVO $5,271 5 payments
  11. Other $12,778 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Celgene Corporation $3,800 1 payment

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record